FDA Bans Red 3 Dye in Foods After Cancer Risk Concerns

US
Published:

The U.S. Food and Drug Administration (FDA) has officially banned the artificial dye known as Red 3 from use in food products, citing cancer risks associated with its consumption. This decision comes nearly 35 years after Red 3 was prohibited in cosmetics due to similar concerns.

The ban, announced on January 15, 2025, follows a petition filed in 2022 by health advocates who urged the FDA to review the safety of the dye, also known as erythrosine or FD&C Red No. 3. The agency emphasized that studies have shown Red 3 caused cancer in laboratory rats, which prompted the legal requirement to remove it under the Delaney Clause, a statute that mandates the ban of any additive found to cause cancer in humans or animals.

Food manufacturers have until January 2027 to eliminate Red 3 from their products, while those producing ingested drugs will have until January 2028 to comply. While some other countries still permit its use in specific applications, all imported foods must adhere to the new U.S. regulations concerning the dye.

Consumer advocates expressed approval of the FDA’s decision. Dr. Peter Lurie, director of the Center for Science in the Public Interest, noted that the prohibition was overdue, highlighting the inconsistency of allowing Red 3 in food products while banning it from cosmetics.

Despite the ban, it remains uncertain whether it will face legal challenges from food manufacturers. The FDA has previously stated that the way Red 3 may induce cancer in rats does not directly translate to effects in humans, leading to years of debate over its safety.

The international community has already moved to ban Red 3 for food use, with regulations in place in Europe, Australia, and New Zealand, while various U.S. states explore similar restrictions.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US